Alnylam Pharmaceuticals, Inc. Savings & Investment Plan
Sponsored by Alnylam Pharmaceuticals, Inc. · EIN 043696884 · Plan #001
- Total assets
- $344M
- Net assets
- $344M
- Active participants
- 1,815
- With balances
- 2,324
Plan year beginning 01/01/2024 · 401(k)
Linked investment advisers
Advisory firms matched from Schedule C service providers (investment codes 26-28).
| Firm | Match | Plan year |
|---|---|---|
| Merrill Lynch, Pierce, Fenner & Smith Incorporated CRD 7691 | fuzzy_auto · 93% | 2024 |
Service providers
Schedule C providers paid $5,000+ (large plans only).
| Provider | Services | Direct comp |
|---|---|---|
| Fidelity Investments Institutional | Participant loan processing, Recordkeeping fees, Account maintenance fees | $250,302 |
| Merrill Lynch Pierce Fenner & Smit | Investment advisory (plan) | $77,297 |
| Rsm Us Llp | Accounting | $34,125 |